Actively Recruiting
Cannabis for Palliative Care in Cancer
Led by University of Colorado, Boulder · Updated on 2025-08-01
185
Participants Needed
1
Research Sites
197 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Many cancer patients suffer from pain, sleep, and mood problems and are using cannabis to relieve these symptoms. Cannabis may provide such relief but may also produce negative side effects including cognitive impairment, an especially problematic issue for cancer patients, indicating more research on cannabis use in the cancer context is required. In this endeavor, the present study seeks to compare the use of hemp-derived CBD (Cannabidiol) with and without THC (Delta-9-tetrahydrocannabinol) versus placebo on measures of sleep, pain, mood, subjective and objective cognitive functioning, and quality of life within 185 cancer patients.
CONDITIONS
Official Title
Cannabis for Palliative Care in Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to provide informed consent
- Aged 25 years or older at baseline
- Diagnosed with any solid tumor and currently undergoing or have undergone curative or palliative treatment in the past 18 months
- Currently experiencing symptoms of sleep problems, pain, and/or mood disturbances such as depression or anxiety
- Desire to use cannabis to treat their symptoms
- Not regularly using cannabis products (more than 3 times per month) in the last 6 months
- Willing to practice acceptable birth control methods until completing study medication
You will not qualify if you...
- Use of illegal drugs (e.g., cocaine, methamphetamine) in the past 90 days
- Current use of anti-epileptic medications such as clobazam, sodium valproate, or lamotrigine
- Current use of medications known to interact with Epidiolex, including buprenorphine, leflunomide, levomethadyl acetate, lomitapide, mipomersen, pexidartinib, propoxyphene, sodium oxybate, and teriflunomide
- Current use of anti-psychotic medications
- Current use of potent CYP2C19 or CYP3A4 inducers such as Rifampin, apalutamide, carbamazepine, enzalutamide, ivosidenib, lumacaftor, ivacaftor, phenytoin, St. John's wort, Fosphenytoin, Mitotane, Phenobarbital, or Primidone
- Liver function tests (ALT and AST) greater than twice the upper normal limit
- Moderate or severe liver disease
- Past or current diagnosis, or family history of psychosis; current major psychiatric illness including bipolar disorder, major depression, or schizophrenia
- History of seizures
- For females of childbearing potential: pregnant, lactating, trying to become pregnant, or lack of confirmed childbearing potential
- Physician indicates contraindications for participation
- Unwillingness to refrain from cannabis use other than study medication during the trial
- Men who consume more than 2 alcoholic drinks per day or women who consume more than 1 alcoholic drink per day
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Anschutz Health Sciences Building
Aurora, Colorado, United States, 80045
Actively Recruiting
Research Team
K
Kyle Chrystal, BA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here